Janus Henderson Group’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $34.4M | Buy |
1,716,412
+145,909
| +9% | +$2.93M | 0.02% | 463 |
|
|
2025
Q1 | $33.1M | Buy |
1,570,503
+238,626
| +18% | +$5.02M | 0.02% | 452 |
|
|
2024
Q4 | $30M | Buy |
1,331,877
+290,153
| +28% | +$6.54M | 0.02% | 504 |
|
|
2024
Q3 | $26.6M | Buy |
1,041,724
+313,019
| +43% | +$8M | 0.01% | 517 |
|
|
2024
Q2 | $17M | Buy |
728,705
+14,794
| +2% | +$345K | 0.01% | 598 |
|
|
2024
Q1 | $12.6M | Buy |
713,911
+305,397
| +75% | +$5.39M | 0.01% | 647 |
|
|
2023
Q4 | $5.68M | Buy |
408,514
+132,098
| +48% | +$1.84M | ﹤0.01% | 786 |
|
|
2023
Q3 | $3.77M | Sell |
276,416
-94,578
| -25% | -$1.29M | ﹤0.01% | 900 |
|
|
2023
Q2 | $7.57M | Sell |
370,994
-231,160
| -38% | -$4.72M | ﹤0.01% | 745 |
|
|
2023
Q1 | $13.2M | Buy |
602,154
+369,977
| +159% | +$8.1M | 0.01% | 658 |
|
|
2022
Q4 | $3.77M | Buy |
+232,177
| New | +$3.77M | ﹤0.01% | 925 |
|